Substances · Cathinone derivatives
Eutylone (bk-EBDB)
- Preferred name
- Eutylone (bk-EBDB)
- IUPAC name
- 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one
- Parent CAS number (reference)
- 802855-66-9
- Molecular formula
- C13H17NO3
- Molecular weight
- 235.28 g/mol
- InChIKey
- YERSNXHEOIYEGX-UHFFFAOYSA-N
- PubChem
- CID 57360686
- Source
- PubChem
- Verified synonyms & catalog abbreviations
-
Eutylone bk-EBDB N-Ethylbutylone
Matching Listings in This Store's Catalog
Verified Neurochemical & Toxicological Intelligence
Eutylone (bk-EBDB / N-Ethylbutylone)
Receptor Telemetry & Mechanism of Action
Hybrid monoamine transporter compound (Glatfelter et al., 2021; WHO 44th ECDD): acts as an uptake blocker at DAT (rat IC50 = 120 ± 10 nM; human hDAT IC50 = 281 ± 80 nM) and NET (rat IC50 = 1,280 ± 140 nM; human hNET IC50 = 700 ± 100 nM), while acting as a weak partial substrate releaser at SERT reaching only 50% of maximal response (human hSERT IC50 = 640 ± 160 nM). This explains why eutylone yields a modest, short-lived MDMA-like warm glow followed by hours of pure dopaminergic/adrenergic stimulation.
Biotransformation & Active Metabolites
Metabolized via beta-ketone reduction, CYP2D6/CYP2C19-catalyzed demethylenation of the benzodioxole ring, COMT O-methylation, and Phase II conjugation. Also promotes antidiuretic hormone (ADH) release, causing temporary urinary difficulty and hyponatremia risk if excess water is consumed.
Temporal Pharmacokinetics
Energetic, sociable cathinone combining a brief, mild entactogenic body tingle and conversational openness with a long, insistent catecholaminergic stimulant tail.
- Onset 15–45 minutes oral (5–15 minutes mucosal)
- Peak Window 1–2 hours oral (30–60 minutes mucosal)
- Total Window 4–8 hours oral (DEA reports effects lasting up to 8 hours; mucosal primary phase 1.5–3 hours)
- Residual / Half-Life 2–24 hours of persistent wakefulness, insomnia, and fatigue; in vivo human elimination half-life is unverified.
Major repeated exposure trap: eutylone's mild empathogenic glow fades rapidly because SERT release caps at 50% maximal efficacy. 'Piggy-backing' extra doses to chase a stronger MDMA-like roll stacks long-lasting DAT/NET blockade—causing up to 8–24 hours of sleeplessness, agitation, tachycardia, rhabdomyolysis, seizures, and documented single-use fatalities as amounts approach or exceed 200 mg.
Quantitative Response Spectrum (Published Literature)
Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.
35 mg
Subtle wakefulness, light mood lift, and mild conversational ease.
Slight dry mouth and gentle increase in pulse.
40–60 mg
Sociable energy, talkativeness, modest emotional warmth, and music enhancement.
Moderate heart-rate rise, light sweating, and appetite suppression.
60–100 mg (WHO forum reports up to 100–200 mg oral; ~50 mg mucosal)
Clear mood elevation, social disinhibition, warm tactile tingling transitioning into alert dopaminergic stimulation.
Elevated heart rate and blood pressure, dry mouth, moderate jaw tension, and ADH-mediated difficulty urinating.
100–180 mg
Forced physical restlessness, vibrating vision (nystagmus), hand unsteadiness, anxiety on offset, and persistent inability to sleep.
Strong tachycardia, hypertension, bruxism, hyperthermia in hot environments, and water-intoxication risk if over-drinking.
180–200+ mg (counterfeit street tablets seized at 300–350 mg linked to severe poisonings)
Acute panic, paranoia, visual hallucinations, agitated delirium, and stimulant psychosis.
Severe hyperthermia, rhabdomyolysis, hypertension, tonic-clonic seizures, and documented fatal intoxication.
Interaction Matrix & Critical Contraindications
Critical Hazard — Never Combine
Partial SERT release plus DAT/NET blockade under MAO inhibition triggers fatal serotonin syndrome, hyperpyrexia, and hypertensive crisis.
Synergistic serotonergic and adrenergic overload precipitates hyperthermia, seizures, rhabdomyolysis, and serotonin toxicity.
Opioid co-ingestions account for fatal eutylone overdoses; co-stimulants cause severe hypertension, vasoconstriction, and seizures.
Elevated Hazard — Avoid
Eutylone promotes ADH release (urinary retention); chugging excessive water causes dangerous water intoxication (hyponatremia), while alcohol worsens overheating and cardiac strain.
Impairs hepatic demethylenation of eutylone, prolonging cardiovascular stimulation and insomnia.
Caution / Receptor Attenuation
Blunts eutylone's already modest partial SERT warmth while leaving long-lasting adrenergic wakefulness intact.
Can heighten heart rate and trigger anxious thought loops during eutylone's protracted offset.
Structural Isomer & Sibling Comparison
Compared to 4-MMC and 3-MMC (full monoamine releasers), eutylone is a hybrid DAT/NET blocker and only a 50%-efficacy partial SERT releaser: its warm 'rolly' phase is noticeably milder and shorter than 4-MMC, while its wakeful stimulant tail lasts longer (up to 8 hours). Compared to MDPHP (which also has a 3,4-methylenedioxy ring), eutylone is ~3-fold gentler per milligram (common 60–100 mg vs. 20–35 mg) and retains mild serotonergic warmth that MDPHP lacks.
Physicochemical Stability & Storage
Form: Odorless crystalline solid or crystals as the hydrochloride salt. · Soluble in water, methanol, and ethanol as the hydrochloride salt.
High analytical stability due to the 3,4-methylenedioxy group (blood sample t1/2 of 31 days at 20 °C in vitro); store dry and protected from light.
Cross-Tolerance & Dependence Profile
Cross-tolerant with all dopaminergic and serotonergic stimulants (4-MMC, 3-MMC, MDMA, NEP); tolerance halves in 3–7 days and resets in 1–2 weeks. High risk of compulsive 'piggy-back' repeated exposure; withdrawal after heavy use involves ~1 week of exhaustion, headaches, tremors, sweating, and low mood.
Chemical Architecture & Structural Profile
Eutylone (bk-EBDB) (1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one) is a reference compound belonging to the Cathinone derivatives class, characterized by the molecular formula C13H17NO3 and a molar mass of 235.28 g/mol. The parent molecule is indexed under CAS registry number 802855-66-9 and in the NCBI PubChem database as CID 57360686 (Standard InChIKey: YERSNXHEOIYEGX-UHFFFAOYSA-N).
Citations
- PubChem — PubChem (2026-11-12)
Reference Toxicology & Safety Profile
In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), Eutylone (bk-EBDB) is indexed within the Cathinone derivatives structural group. As a substituted beta-ketone (cathinone derivative), this compound requires strict analytical verification and has documented contraindications with MAOIs, serotonergic agents, and other stimulants. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.
Citations
- PubChem — PubChem (2026-11-12)
Analytical Use & Laboratory Notice
This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.
Citations
- Gesetze im Internet — Neue-psychoaktive-Stoffe-Gesetz (NpSG) & BtMG — Bundesministerium der Justiz (2026-11-12)